Skip to main content

Market Overview

Several Recent Developments Have Zika-Related Stocks Rallying Over Last Few Days

Several Recent Developments Have Zika-Related Stocks Rallying Over Last Few Days

There are at least two stocks -- Intrexon Corporation (NYSE: XON) and Inovio Pharmaceuticals, Inc. (NASDAQ: INO) -- that continued to get more attention from investors. That's because these stocks and Cerus Corporation (NASDAQ: CERS) shares are likely to gain from the Zika Virus.

The threat of Zika virus is spreading. Most recently, Miami called on the Centers for Disease Control and Prevention to send them an emergency response team to help their investigation of the local cases. The outbreak has led to 10 more local cases in the region.

The CDC also an advisory note advising women not to travel to the area. CDC also advised women to wait for a minimum of eight weeks before trying for a pregnancy.

The disease has been spread mostly by infected mosquitoes.

Related Link: A Timeline Of The Zika Virus Spread

Last week, Inovia revealed the closing of the first subject in its first stage study to assess Zika DNA vaccine. The interest for the stock has grown since after the phase I, open-label, dose-ranging trial of 40 healthy adult volunteers was assessing the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P device.

In the last six trading sessions, Inovio moved up by 13.9 percent, while Intrexon shares surged 14.1 percent. Similarly Cerus advanced 13.1 percent in the last six trading sessions.


Related Articles (INO + CERS)

View Comments and Join the Discussion!

Posted-In: Zika Zika VirusNews Health Care Trading Ideas Press Releases General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at